Dabrafenib in metastatic melanoma: A monocentric 'real life' experience

E. Cocorocchio, S. Gandini, S. Alfieri, A. Battaglia, E. Pennacchioli, G. Tosti, G. Spadola, M. Barberis, M. Di Leo, C. Riviello, L. Pala, A. Intelisano, C. Martinoli, P. F. Ferrucci

Research output: Contribution to journalArticlepeer-review


Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR, 62% PR, 13% SD and 18% PD. The median PFS and OS were seven and 17 months, respectively (median follow-up: 8.5 months). Increased risk of progression was found in pts with elevated LDH, ECOG PS >1 and more than two metastatic sites. Grade 3-4 adverse events were recorded in 4 pts. In this retrospective analysis, Dabrafenib confirmed its role as the standard clinical option in metastatic melanoma pts.

Original languageEnglish
Article number624
Publication statusPublished - Mar 3 2016


  • BRAF V600 mutation
  • Dabrafenib
  • Metastatic melanoma
  • Target therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Dabrafenib in metastatic melanoma: A monocentric 'real life' experience'. Together they form a unique fingerprint.

Cite this